Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zemprocitinib - Lynk Pharmaceuticals

Next Previous
Drug Profile

Zemprocitinib - Lynk Pharmaceuticals

Alternative Names: EQ-121; LNK-01001; LNK-207

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lynk Pharmaceuticals
  • Developer EQRx; Lynk Pharmaceuticals; Simcere Pharmaceutical Group
  • Class Alkanes; Anti-inflammatories; Antirheumatics; Bridged bicyclo compounds; Pyrazoles; Pyridines; Pyrroles; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Rheumatoid arthritis
  • Phase II Ankylosing spondylitis; Psoriasis
  • Phase I Alopecia areata; Hidradenitis suppurativa; Ulcerative colitis; Vitiligo

Most Recent Events

  • 30 Oct 2025 Chemical structure information added.
  • 13 Oct 2025 Phase-I clinical trials in Alopecia areata (PO) before October 2025 (Lynk Pharmaceuticals pipeline, October 2025)
  • 13 Oct 2025 Phase-I clinical trials in Hidradenitis suppurativa (PO) before October 2025 (Lynk Pharmaceuticals pipeline, October 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top